Sundial Growers Inc. (“Sundial”) has signed a three (3) year Memorandum of Understanding for Collaborative Research with the University of Calgary related to research and clinical studies of cannabis for medicinal purposes. The partnership aligns with the University of Calgary’s strategic research areas of brain and mental health, as well as infections, inflammation and chronic diseases.

“Sundial is thrilled to sign this partnership agreement with the University of Calgary and we look forward to working with the Cumming School of Medicine’s Hotchkiss Brain Institute, as well as other institutes and departments, to find opportunities for world-class research and clinical studies of cannabis strains for medicinal purposes,” said Sundial’s President, Geoff Thompson. “Partnership agreements with world-class research institutions such as the University of Calgary are important for Sundial as we work towards becoming a leading international medical cannabis company.” 

Through the agreement, the University of Calgary and Sundial will work together to define and implement research and clinical studies that meet the strategic goals of both organizations. The parties will also look to create opportunities to sponsor specific trainees and faculty for projects related to the advancement of the understanding of medicinal applications of cannabis and to secure partnership funding to establish research chairs and trainee sponsorships for specific research projects.

“Early research into the possible benefits of medicinal cannabis shows promise. This agreement with Sundial will put the University of Calgary at the forefront of the scientific advancement of medicinal cannabis as a treatment option for a number of medical conditions,” said Dr. Keith Sharkey, Interim Director, Hotchkiss Brain Institute. “Sundial’s approach to growing cannabis in their specialized cultivation modules makes them a strong partner for the University of Calgary, which needs a consistent and quality supply of cannabis for research purposes.”

Sundial and the University of Calgary will collaborate over the coming months to develop projects of mutual interest to both parties. Once projects are determined, the parties will enter into separate Project Agreements that will define specific goals and be governed by standard clinical trial protocols.